Carlos E. Ibañez
Founder at Abintus Bio, Inc.
Profile
Carlos E.
Ibañez is the founder.
He founded Abintus Bio, Inc. in 2020 and currently holds the title of Senior Vice President-CMC.
Dr. Ibañez also held former positions at Chiron Corp., Collateral Therapeutics, Inc., Activate Immunotherapy, Tocagen, Inc., Chiron Viagene, Inc., and the Research Institute of Public Health.
At Chiron Corp., Collateral Therapeutics, Inc., Activate Immunotherapy, and Chiron Viagene, Inc., he held the title of Principal.
At Tocagen, Inc., he held the title of Vice President-Product Development & Manufacturing.
Dr. Ibañez obtained a doctorate degree from the University of California San Diego.
Carlos E. Ibañez active positions
Companies | Position | Start |
---|---|---|
Abintus Bio, Inc.
Abintus Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Abintus Bio, Inc. operates as a preclinical stage gene therapy company. It provides immune cell reprogramming services. The company was founded by John Snyder, Nicholas A. Boyle, Douglas J. Jolly, Carlos Ibañez, Derek Ostertag, and Cory Bentley and is headquartered in Encinitas, CA. | Founder | 15/04/2020 |
Former positions of Carlos E. Ibañez
Companies | Position | End |
---|---|---|
Research Institute of Public Health | Corporate Officer/Principal | - |
Activate Immunotherapy
Activate Immunotherapy BiotechnologyHealth Technology Activate Immunotherapy operates as a clinical-stage biopharmaceutical company. The firm discovers, develops, and commercializes Immunotherapies for the treatment of cancer. The company was founded by Habib Fakhrai and Emmet O’Neal III in 1997 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Corporate Officer/Principal | - |
Training of Carlos E. Ibañez
University of California San Diego | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 7 |
---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Commercial Services |
Activate Immunotherapy
Activate Immunotherapy BiotechnologyHealth Technology Activate Immunotherapy operates as a clinical-stage biopharmaceutical company. The firm discovers, develops, and commercializes Immunotherapies for the treatment of cancer. The company was founded by Habib Fakhrai and Emmet O’Neal III in 1997 and is headquartered in San Diego, CA. | Health Technology |
Tocagen, Inc.
Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Commercial Services |
Research Institute of Public Health | |
Abintus Bio, Inc.
Abintus Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Abintus Bio, Inc. operates as a preclinical stage gene therapy company. It provides immune cell reprogramming services. The company was founded by John Snyder, Nicholas A. Boyle, Douglas J. Jolly, Carlos Ibañez, Derek Ostertag, and Cory Bentley and is headquartered in Encinitas, CA. | Commercial Services |
- Stock Market
- Insiders
- Carlos E. Ibañez